Vericel Corporation (VCEL) Stock Price & How to Invest

Vericel Corporation is a Cambridge, Massachusetts commercial-stage biopharma focused on advanced cell therapies for sports medicine and severe burn care. Its lead product, MACI, is an autologous cultured chondrocyte implant that grows a patient's own cartilage cells on a collagen membrane to repair symptomatic knee cartilage defects, and it anchors roughly 80% of revenue. The burn-care franchise adds Epicel, a permanent skin replacement for severe burns, and NexoBrid, an enzymatic agent that removes dead burn tissue, the latter supported by a multi-year BARDA procurement agreement.

The investment picture is a profitable, self-funding growth company rather than a speculative biotech. Trailing-twelve-month revenue is around $292M with modest positive net income, roughly 72-75% gross margins, positive free cash flow, over $200M of cash and investments, and no debt. The 2026 story centers on a newly FDA-approved MACI manufacturing facility that expands capacity, potential geographic expansion (a prospective UK launch), and continued double-digit growth. The tension is valuation: the stock trades at a high multiple of sales and earnings, so the market is already pricing in years of execution.

The stock trades at a rich multiple (high price-to-sales and a triple-digit trailing price-to-earnings), so any growth slowdown or quarterly miss can trigger sharp drawdowns, as the Q1 2026 GAAP loss reminded investors. Revenue is heavily concentrated in a single product, MACI, and depends on elective orthopedic procedure volumes that can soften in a weak economy. Reimbursement changes, surgeon-adoption pace, and the complexity of a personalized cell-manufacturing supply chain are ongoing execution risks. Larger orthopedics players such as Smith+Nephew, Stryker and Arthrex could pressure the broader cartilage-repair space over time. Burn-care revenue can be lumpy and partly dependent on government contracts.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Vericel Corporation's investor relations page or your broker.

• Revenue (TTM): ~$292M
• Net income (TTM): ~$22M
• Market cap: ~$2.3B
• Gross margin: ~72-75%
• Cash & investments: ~$211M (no debt)
• 2026 revenue guidance: ~$326-336M

VCEL trades at roughly 8x trailing sales and a triple-digit trailing P/E, a growth-stock valuation that reflects durable 20-30% revenue growth and expanding margins rather than current earnings. Q1 2026 revenue rose about 30% to $68.4M even as the company posted a small GAAP net loss, and management raised full-year guidance. The premium multiple leaves little room for execution missteps.

There are three common ways to get VCEL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so VCEL sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where VCEL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

VCEL is a durable, growing cell-therapy franchise trading at a rich multiple, where the debate is valuation and execution, not survival.

Whether VCEL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is VCEL a buy?, and where the stock could go from here in the VCEL stock forecast.

For income investors, whether VCEL pays a dividend and how the payout looks is covered in does VCEL pay a dividend?